Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over

Final draft guidance

Final draft guidance (PDF 276 KB)

Committee papers (PDF 9.02 MB)

Public committee slides (PDF 926 KB)

Equality impact assessment (PDF 151 KB)

Register of interests (PDF 154 KB)

Committee meeting: 1

Topic Register of Interest (MSWord 44 KB)

Final scope (PDF 177 KB)

Provisional Stakeholder List (post-referral) (PDF 193 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 180 KB)

Equality impact assessment (Scoping) (PDF 126 KB)